Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.
Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.
The declining trend in Sinopharm Group's ROCE and the stock's 42% fall in the last five years doesn't inspire investor confidence. The article doesn't consider Sinopharm Group as a potential multi-bagger based on the present analysis.
$国薬(01099.HK)$ It's dropping just because of morgamnstanley downgrades, which at best is right 3 out of 10 times. Dont listen to these analysts which have lots of vested interest. Chinese govt has a saying, polish your knives and make the kill when opportunity comes.... This company has lots of researchers on it and stay humble without bleating data unlike western counterparts. Wont be long before a breakthrough vaccine or medicine will come through with all the resources and financial muscle it has...
1
1
報告
Charstey :
I believe that a suitable vaccine will come out soon, and its decline is only temporary
SINOPHARM GROUP COに関するコメント
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
It's dropping just because of morgamnstanley downgrades, which at best is right 3 out of 10 times. Dont listen to these analysts which have lots of vested interest. Chinese govt has a saying, polish your knives and make the kill when opportunity comes.... This company has lots of researchers on it and stay humble without bleating data unlike western counterparts. Wont be long before a breakthrough vaccine or medicine will come through with all the resources and financial muscle it has...
まだコメントはありません